Olmesartan Associated Enteropathy, an easily overlooked etiology of bowel disturbance: report of three cases

Authors

  • Khan Mohammad Nazmus Saqeb Assistant Professor, Dept. of Gastrointestinal, Hepatobiliary & Pancreatic diseases, Jahurul Islam Medical College & Hospital, Kishoreganj, Bangladesh
  • Muskan Manzoor Intern doctor, Dept. of Internal Medicine, Shri Maharaja Hari Singh Hospital, Srinagar, Jammu and Kashmir, India
  • Lutful L Chowdhury Senior Consultant & Coordinator, Dept. of Gastroenterology, Evercare Hospital, Dhaka, Bangladesh
  • Mohammad Shamsul Arfin Professor, Chief Consultant & Head, Dept. of Gastrointestinal, Hepatobiliary & Pancreatic diseases, Bangladesh Specialized Hospital, Dhaka, Bangladesh

DOI:

https://doi.org/10.3329/bccj.v10i2.62211

Keywords:

Olmesartan, Coeliac disease, Olmesartan Associated Enteropathy

Abstract

Olmesartan medoxomil is one of eight marketed Angiotensin II Receptor Blocker for the treatment of high blood pressure. Olmesartan Associated Enteropathy has been described in several case reports, subsequently, the United states Food and Drug Administrationincluded severe sprue-like enteropathy as an adverse effect of Olmesartan. Olmesartan Associated Enteropathy mimics celiac disease clinically and pathologically. The pathologic findings are villous atrophy and increased intraepithelial lymphocytes. Clinical presentation of Olmesartan Associated Enteropathy includes nausea, bloating, diarrhea and weight loss. In contrast to celiac disease, tissue transglutaminase is not elevated, and there is no response to a gluten-free diet. Several case reports have described the effects of olmesartan on gut, giving rise to the term of Olmesartan Associated Enteropathy. Clinicians should always be aware that Olmesartan can cause an enteropathy clinically and histologically similar to celiac disease since replacing Olmesartan with an alternative antihypertensive drug can simplify the diagnostic workup and provide both clinical and histologic improvement. We report three cases of Olmesartan Associated Enteropathy in this article.

Bangladesh Crit Care J September 2022; 10(2): 154-157

Downloads

Download data is not yet available.
Abstract
114
PDF
118

Downloads

Published

2022-10-18

How to Cite

Nazmus Saqeb, K. M. ., Manzoor, M. ., Chowdhury, L. L., & Arfin, M. S. . (2022). Olmesartan Associated Enteropathy, an easily overlooked etiology of bowel disturbance: report of three cases. Bangladesh Critical Care Journal, 10(2), 154–157. https://doi.org/10.3329/bccj.v10i2.62211

Issue

Vol. 10 No. 2 (2022)

Section

Case Reports

License

Upon acceptance for publication the copyright of the paper automatically transfers to the BCCJ and will not be published elsewhere either in part or whole without written permission of the copyright holder.

Except for personal use, no part of the materials published in this journal may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, photocopying, recording or otherwise without the prior written permission of the publisher.